Symbols / CHRS Stock $1.45 -7.94% Coherus Oncology, Inc.

Healthcare • Biotechnology • United States • NGM
CHRS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Dennis M. Lanfear
Exch · Country NGM · United States
Market Cap 223.66M
Enterprise Value 110.99M
Income -172.66M
Sales 46.88M
FCF (ttm) -27.06M
Book/sh 0.51
Cash/sh 1.08
Employees 145
Insider 10d —
IPO Nov 06, 2014
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 3.07
Forward P/E -1.42
PEG —
P/S 4.77
P/B 2.84
P/C —
EV/EBITDA -0.68
EV/Sales 2.37
Quick Ratio 1.43
Current Ratio 1.56
Debt/Eq 69.16
LT Debt/Eq —
EPS (ttm) -1.42
EPS next Y -1.02
EPS Growth —
Revenue Growth 62.00%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-11
ROA -32.80%
ROE —
ROIC —
Gross Margin 68.06%
Oper. Margin -293.67%
Profit Margin 3.97%
Shs Outstand 154.25M
Shs Float 132.53M
Insider Own 18.54%
Instit Own 38.56%
Short Float 18.78%
Short Ratio 20.69
Short Interest 28.11M
52W High 2.62
vs 52W High -44.57%
52W Low 0.71
vs 52W Low 104.23%
Beta 0.96
Impl. Vol. 3.00%
Rel Volume 0.70
Avg Volume 1.28M
Volume 896.89K
Target (mean) $7.80
Tgt Median $7.00
Tgt Low $4.00
Tgt High $12.00
# Analysts 5
Recom Strong_buy
Prev Close $1.57
Price $1.45
Change -7.94%
About

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$7.80
Mean price target
2. Current target
$1.45
Latest analyst target
3. DCF / Fair value
$-3.16
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.45
Low
$4.00
High
$12.00
Mean
$7.80

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-11 init Guggenheim — → Buy $12
2026-01-22 init Oppenheimer — → Outperform $10
2025-09-04 up Maxim Group Hold → Buy $4
2025-04-29 reit HC Wainwright & Co. Buy → Buy $7
2025-04-24 main UBS Neutral → Neutral $1
2025-03-11 reit HC Wainwright & Co. Buy → Buy $7
2025-01-23 reit HC Wainwright & Co. Buy → Buy $7
2025-01-22 reit HC Wainwright & Co. Buy → Buy $7
2024-12-05 main Baird Outperform → Outperform $6
2024-12-04 reit HC Wainwright & Co. Buy → Buy $7
2024-11-08 main Baird Outperform → Outperform $4
2024-11-07 reit HC Wainwright & Co. Buy → Buy $12
2024-09-16 reit HC Wainwright & Co. Buy → Buy $12
2024-08-16 down UBS Buy → Neutral $2
2024-08-05 reit HC Wainwright & Co. Buy → Buy $12
2024-07-01 main Baird Outperform → Outperform $8
2024-05-24 reit HC Wainwright & Co. Buy → Buy $12
2024-05-13 main Truist Securities Buy → Buy $7
2024-05-10 main HC Wainwright & Co. Buy → Buy $12
2024-03-20 main HC Wainwright & Co. Buy → Buy $11
News
RSS: Latest CHRS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-23 LANFEAR DENNIS M Chief Executive Officer — 375,000 $0.00 $0
2026-01-22 MCMICHAEL BRYAN J Chief Financial Officer — 112,500 $0.00 $0
2025-05-23 WAHLSTROM MATS Director — 99,988 $0.74 $73,881
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
42.17
+59.81%
26.39
-89.74%
257.24
+21.89%
211.04
Operating Revenue
42.17
+59.81%
26.39
-89.74%
257.24
+21.89%
211.04
Cost Of Revenue
13.81
+58.29%
8.73
-94.51%
158.99
+126.86%
70.08
Reconciled Cost Of Revenue
13.81
+58.29%
8.73
-94.51%
158.99
+126.86%
70.08
Gross Profit
28.36
+60.56%
17.66
-82.02%
98.25
-30.30%
140.96
Operating Expense
209.49
-3.60%
217.31
-27.91%
301.45
-24.23%
397.84
Research And Development
108.89
+18.57%
91.83
-16.09%
109.44
-45.11%
199.36
Selling General And Administration
100.60
-19.83%
125.48
-34.65%
192.01
-3.26%
198.48
Total Expenses
223.31
-1.21%
226.04
-50.91%
460.44
-1.60%
467.92
Operating Income
-181.13
+9.28%
-199.65
+1.75%
-203.20
+20.90%
-256.88
Total Operating Income As Reported
-181.13
+9.28%
-199.65
+1.75%
-203.20
+20.90%
-256.88
EBITDA
-170.20
+14.64%
-199.38
-2.81%
-193.94
+24.12%
-255.58
Normalized EBITDA
-170.20
+8.86%
-186.75
+3.70%
-193.94
+22.22%
-249.36
Reconciled Depreciation
3.92
-25.63%
5.28
+39.17%
3.79
+2.49%
3.70
EBIT
-174.12
+14.92%
-204.66
-3.50%
-197.73
+23.74%
-259.28
Total Unusual Items
0.00
+100.00%
-12.63
0.00
+100.00%
-6.22
Total Unusual Items Excluding Goodwill
0.00
+100.00%
-12.63
0.00
+100.00%
-6.22
Special Income Charges
0.00
+100.00%
-12.63
0.00
+100.00%
-6.22
Other Special Charges
—
12.63
—
6.22
Net Income
168.02
+489.41%
28.51
+111.98%
-237.89
+18.46%
-291.75
Pretax Income
-183.12
+14.98%
-215.39
+9.60%
-238.27
+18.33%
-291.75
Net Non Operating Interest Income Expense
-9.00
+16.14%
-10.73
+73.52%
-40.54
-24.84%
-32.47
Interest Expense Non Operating
9.00
-16.14%
10.73
-73.52%
40.54
+24.84%
32.47
Net Interest Income
-9.00
+16.14%
-10.73
+73.52%
-40.54
-24.84%
-32.47
Interest Expense
9.00
-16.14%
10.73
-73.52%
40.54
+24.84%
32.47
Other Income Expense
7.01
+240.02%
-5.01
-191.55%
5.47
+327.88%
-2.40
Other Non Operating Income Expenses
7.01
-8.03%
7.62
+39.39%
5.47
+43.09%
3.82
Gain On Sale Of Business
—
176.59
0.00
0.00
Tax Provision
0.00
0.00
+100.00%
-0.38
0.00
Tax Rate For Calcs
0.00
0.00
-100.00%
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
168.02
+489.41%
28.51
+111.98%
-237.89
+18.46%
-291.75
Net Income From Continuing Operation Net Minority Interest
-183.12
+14.98%
-215.39
+9.46%
-237.89
+18.46%
-291.75
Net Income From Continuing And Discontinued Operation
168.02
+489.41%
28.51
+111.98%
-237.89
+18.46%
-291.75
Net Income Continuous Operations
-183.12
+14.98%
-215.39
+9.46%
-237.89
+18.46%
-291.75
Net Income Discontinuous Operations
351.15
+43.97%
243.90
—
—
Normalized Income
-183.12
+9.69%
-202.76
+14.77%
-237.89
+16.68%
-285.53
Net Income Common Stockholders
168.02
+489.41%
28.51
+111.98%
-237.89
+18.46%
-291.75
Diluted EPS
1.43
+472.00%
0.25
+109.88%
-2.53
+32.71%
-3.76
Basic EPS
1.43
+472.00%
0.25
+109.88%
-2.53
+32.71%
-3.76
Basic Average Shares
117.14
+2.26%
114.55
+21.65%
94.16
+21.30%
77.63
Diluted Average Shares
117.14
+2.01%
114.83
+21.95%
94.16
+21.30%
77.63
Diluted NI Availto Com Stockholders
168.02
+489.41%
28.51
+111.98%
-237.89
+18.46%
-291.75
Average Dilution Earnings
—
—
—
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
258.34
-42.40%
448.53
-28.76%
629.60
+30.94%
480.85
Current Assets
206.71
-39.49%
341.58
-28.18%
475.63
+24.76%
381.23
Cash Cash Equivalents And Short Term Investments
172.12
+36.62%
125.99
+7.00%
117.75
-38.57%
191.68
Cash And Cash Equivalents
88.88
-29.45%
125.99
+22.45%
102.89
+61.91%
63.55
Other Short Term Investments
83.25
0.00
-100.00%
14.86
-88.41%
128.13
Receivables
18.42
-84.94%
122.33
-53.04%
260.52
+136.92%
109.96
Accounts Receivable
17.82
-84.00%
111.32
-57.27%
260.52
+136.92%
109.96
Other Receivables
0.60
-94.52%
11.01
—
—
Inventory
3.17
-24.60%
4.21
-93.28%
62.60
+61.39%
38.79
Prepaid Assets
6.76
+1.58%
6.65
-71.88%
23.66
+32.31%
17.88
Assets Held For Sale Current
0.00
-100.00%
72.18
—
—
Other Current Assets
6.23
-39.02%
10.22
-7.90%
11.10
-51.57%
22.92
Total Non Current Assets
51.64
-51.72%
106.95
-30.54%
153.97
+54.57%
99.61
Net PPE
1.34
-47.79%
2.58
-49.68%
5.12
-41.52%
8.75
Gross PPE
16.58
-29.65%
23.56
-8.56%
25.77
-10.86%
28.91
Accumulated Depreciation
-15.23
+27.42%
-20.99
-1.63%
-20.65
-2.45%
-20.16
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
10.81
-40.16%
18.07
+1.97%
17.73
+1.96%
17.39
Construction In Progress
—
—
0.00
-100.00%
0.70
Other Properties
—
-0.26
-111.38%
2.29
-50.47%
4.63
Leases
5.76
+0.21%
5.75
+0.00%
5.75
-7.21%
6.20
Goodwill And Other Intangible Assets
46.24
-13.81%
53.65
-25.15%
71.67
+1108.45%
5.93
Goodwill
—
0.00
-100.00%
0.94
+0.00%
0.94
Other Intangible Assets
46.24
-13.81%
53.65
-24.15%
70.73
+1318.00%
4.99
Other Non Current Assets
4.05
-92.01%
50.73
-34.27%
77.18
-9.12%
84.93
Total Liabilities Net Minority Interest
197.33
-66.01%
580.52
-29.47%
823.03
+33.12%
618.26
Current Liabilities
141.88
-49.86%
282.98
-14.71%
331.77
+139.21%
138.69
Payables And Accrued Expenses
123.98
-50.27%
249.33
-19.08%
308.11
+175.67%
111.77
Payables
9.91
-65.16%
28.46
-19.20%
35.22
+205.56%
11.53
Accounts Payable
9.91
-65.16%
28.46
-19.20%
35.22
+205.56%
11.53
Current Accrued Expenses
114.06
-48.36%
220.87
-19.06%
272.89
+172.23%
100.24
Pensionand Other Post Retirement Benefit Plans Current
14.58
-20.52%
18.34
-14.76%
21.52
-4.82%
22.61
Current Debt And Capital Lease Obligation
1.83
+8.10%
1.69
-21.17%
2.15
-50.32%
4.32
Current Capital Lease Obligation
1.83
+8.10%
1.69
-21.17%
2.15
-50.32%
4.32
Other Current Liabilities
1.49
-89.06%
13.62
—
—
Total Non Current Liabilities Net Minority Interest
55.45
-81.36%
297.54
-39.43%
491.26
+2.44%
479.57
Long Term Debt And Capital Lease Obligation
38.51
-85.64%
268.21
-43.97%
478.70
+0.54%
476.10
Long Term Debt
37.05
-86.01%
264.93
-44.03%
473.37
+0.49%
471.06
Long Term Capital Lease Obligation
1.46
-55.66%
3.29
-38.33%
5.33
+5.59%
5.05
Non Current Deferred Liabilities
1.10
+0.00%
1.10
+0.00%
1.10
0.00
Non Current Deferred Taxes Liabilities
1.10
+0.00%
1.10
+0.00%
1.10
0.00
Other Non Current Liabilities
15.84
-43.87%
28.23
+146.33%
11.46
+230.52%
3.47
Stockholders Equity
61.01
+146.23%
-131.99
+31.76%
-193.43
-40.76%
-137.42
Common Stock Equity
61.01
+146.23%
-131.99
+31.76%
-193.43
-40.76%
-137.42
Capital Stock
0.01
+0.00%
0.01
+9.09%
0.01
+37.50%
0.01
Common Stock
0.01
+0.00%
0.01
+9.09%
0.01
+37.50%
0.01
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
121.15
+4.79%
115.61
+3.03%
112.22
+42.31%
78.85
Ordinary Shares Number
121.15
+4.79%
115.61
+3.03%
112.22
+42.31%
78.85
Additional Paid In Capital
1,444.17
+1.75%
1,419.27
+2.38%
1,386.31
+15.10%
1,204.43
Retained Earnings
-1,382.97
+10.83%
-1,550.99
+1.80%
-1,579.50
-17.73%
-1,341.61
Gains Losses Not Affecting Retained Earnings
-0.20
+29.09%
-0.28
-10.89%
-0.25
+0.40%
-0.25
Other Equity Adjustments
-0.20
+29.09%
-0.28
-10.89%
-0.25
+0.40%
-0.25
Total Equity Gross Minority Interest
61.01
+146.23%
-131.99
+31.76%
-193.43
-40.76%
-137.42
Total Capitalization
98.06
-26.23%
132.94
-52.51%
279.94
-16.09%
333.64
Working Capital
64.83
+10.63%
58.60
-59.26%
143.86
-40.69%
242.54
Invested Capital
98.06
-26.23%
132.94
-52.51%
279.94
-16.09%
333.64
Total Debt
40.34
-85.06%
269.90
-43.87%
480.84
+0.09%
480.42
Net Debt
—
138.94
-62.50%
370.48
-9.09%
407.51
Capital Lease Obligations
3.29
-34.00%
4.98
-33.40%
7.47
-20.19%
9.36
Net Tangible Assets
14.78
+107.96%
-185.64
+29.97%
-265.10
-84.93%
-143.35
Tangible Book Value
14.78
+107.96%
-185.64
+29.97%
-265.10
-84.93%
-143.35
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-138.51
-577.66%
-20.44
+88.31%
-174.88
+27.47%
-241.12
Cash Flow From Continuing Operating Activities
-138.51
-577.66%
-20.44
+88.31%
-174.88
+27.47%
-241.12
Net Income From Continuing Operations
168.02
+489.41%
28.51
+111.98%
-237.89
+18.46%
-291.75
Depreciation Amortization Depletion
3.92
-25.63%
5.28
+39.17%
3.79
+2.49%
3.70
Depreciation And Amortization
3.92
-25.63%
5.28
+39.17%
3.79
+2.49%
3.70
Other Non Cash Items
-10.33
-12695.12%
0.08
+321.62%
-0.04
-100.45%
8.23
Stock Based Compensation
16.97
-38.98%
27.80
-35.51%
43.11
-15.03%
50.74
Asset Impairment Charge
4.16
-80.09%
20.91
-60.23%
52.59
+102.29%
26.00
Operating Gains Losses
-315.42
-98.48%
-158.92
-42477.60%
0.38
-99.09%
41.22
Gain Loss On Investment Securities
12.61
+150.01%
5.04
+1244.80%
0.38
-98.93%
35.00
Change In Working Capital
-5.84
-110.45%
55.89
+251.78%
-36.83
+53.54%
-79.26
Change In Receivables
93.56
-37.36%
149.35
+199.12%
-150.68
-1254.48%
13.05
Changes In Account Receivables
93.56
-37.36%
149.35
+199.12%
-150.68
-1254.48%
13.05
Change In Inventory
-17.11
+46.46%
-31.95
+31.63%
-46.73
+1.30%
-47.35
Change In Prepaid Assets
5.11
+33.56%
3.83
-78.96%
18.18
+203.08%
-17.64
Change In Payables And Accrued Expense
-151.85
-132.43%
-65.33
-145.87%
142.41
+621.21%
-27.32
Change In Accrued Expense
-132.29
-115.49%
-61.39
-151.74%
118.65
+620.96%
-22.77
Change In Payable
-19.56
-396.60%
-3.94
-116.57%
23.76
+622.43%
-4.55
Change In Account Payable
-19.56
-396.60%
-3.94
-116.57%
23.76
+622.43%
-4.55
Change In Other Working Capital
64.45
—
—
0.60
Investing Cash Flow
375.09
+62.85%
230.32
+59.24%
144.64
+186.69%
-166.85
Cash Flow From Continuing Investing Activities
375.09
+62.85%
230.32
+59.24%
144.64
+186.69%
-166.85
Net PPE Purchase And Sale
—
—
0.56
+127.42%
-2.04
Purchase Of PPE
—
—
-0.29
+85.97%
-2.04
Sale Of PPE
—
—
0.84
0.00
Capital Expenditure
—
—
-0.29
+85.97%
-2.04
Net Investment Purchase And Sale
-82.38
-653.30%
14.89
-89.22%
138.13
+208.44%
-127.38
Purchase Of Investment
-103.84
0.00
+100.00%
-19.51
+84.69%
-127.38
Sale Of Investment
21.46
+44.16%
14.89
-90.56%
157.64
0.00
Net Business Purchase And Sale
457.81
+112.61%
215.32
+2977.36%
7.00
+119.99%
-35.00
Purchase Of Business
-12.50
+0.00%
-12.50
0.00
+100.00%
-35.00
Gain Loss On Sale Of Business
-338.31
-91.58%
-176.59
0.00
0.00
Net Other Investing Changes
-0.34
-410.91%
0.11
+122.36%
-0.49
+88.99%
-4.47
Financing Cash Flow
-273.70
-46.39%
-186.97
-368.64%
69.60
+28.12%
54.33
Cash Flow From Continuing Financing Activities
-273.70
-46.39%
-186.97
-368.64%
69.60
+28.12%
54.33
Net Issuance Payments Of Debt
-280.84
-25.71%
-223.41
0.00
-100.00%
49.93
Issuance Of Debt
—
36.98
0.00
-100.00%
240.68
Repayment Of Debt
-280.84
-7.85%
-260.39
0.00
+100.00%
-190.75
Long Term Debt Issuance
—
36.98
0.00
-100.00%
240.68
Long Term Debt Payments
-280.84
-7.85%
-260.39
0.00
+100.00%
-190.75
Net Long Term Debt Issuance
-280.84
-25.71%
-223.41
0.00
-100.00%
49.93
Net Common Stock Issuance
7.89
+442.54%
1.46
-97.97%
71.72
+1028.00%
6.36
Proceeds From Stock Option Exercised
0.35
-61.88%
0.93
-63.00%
2.50
-16.87%
3.01
Net Other Financing Charges
-1.11
-103.27%
34.05
+836.92%
-4.62
+7.06%
-4.97
Changes In Cash
-37.13
-262.09%
22.91
-41.80%
39.36
+111.13%
-353.65
Effect Of Exchange Rate Changes
—
—
—
—
Beginning Cash Position
126.25
+22.17%
103.34
+61.51%
63.99
-84.68%
417.63
End Cash Position
89.12
-29.41%
126.25
+22.17%
103.34
+61.51%
63.99
Free Cash Flow
-138.51
-577.66%
-20.44
+88.31%
-174.88
+27.47%
-241.12
Interest Paid Supplemental Data
9.92
-60.92%
25.38
-32.97%
37.86
+8.54%
34.88
Income Tax Paid Supplemental Data
0.04
—
—
0.04
Amortization Of Securities
—
—
-3.05
-318.08%
-0.73
Common Stock Issuance
7.89
+442.54%
1.46
-97.97%
71.72
+1028.00%
6.36
Issuance Of Capital Stock
7.89
+442.54%
1.46
-97.97%
71.72
+1028.00%
6.36
Sale Of Business
470.31
+106.43%
227.82
+3156.01%
7.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category